# RCT-PAAG (NCT06051851)

> Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

No report yet. It can be ordered.

- Drugs tested: penpulimab plus anlotinib
- Indication: first-line metastatic pancreatic adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06051851
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Conditions: Pancreatic Adenocarcinoma Metastatic
- Interventions: Penpulimab; Anlotinib; Nab paclitaxel; Gemcitabine
- Enrollment: 177
- Primary outcome: Progression-free survival（PFS）

## Indexed commentary on RCT-PAAG so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rct-paag-nct06051851